Scientific Publications

Low-frequency CD8+ T cells induced by SIGN-R1+ macrophage-targeted vaccine confer SARS-CoV-2 clearance in mice.

Muraoka D, Moi ML, Muto O, et al. (2024) NPJ Vaccines Sep 18;9(1):173.

A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.

Ishihara M, Nishida Y, et al. (2023) Int J Cancer. Jun 15;152(12):2554-2566

Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance.

Muraoka D, Harada N, Shiku H, Akiyoshi K. (2022) J Control Release. Jul;347:175-182

Identification of a dominant CD8+ CTL epitope in the SARS-associated coronavirus 2 spike protein.

Muraoka D, Situo D, Sawada SI, Akiyoshi K, Harada N, Ikeda H.(2020) Vaccine. Nov 17;38(49):7697-7701

Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance.

Muraoka D, Seo N, Hayashi T, Tahara Y, et al. (2019) J Clin Invest. 129(3):1278-1294.

Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity.

Muraoka D, Harada N, Hayashi T, et al. (2014) ACS Nano. Sep 23;8(9):9209-18

We want to provide you with the most important information and services in the best possible way. In order to do this, we need your consent to use the web analysis tool »Google Analytics« to create and evaluate an anonymous analysis of your visit for statistical purposes. You can change your consent at any time on the data protection page, otherwise it will remain valid for twelve months.